# Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

> **NCT03374488** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 84 (actual)

## Conditions studied

- UC (Urothelial Cancer)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Epacadostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03374488
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-22
- **Primary completion:** 2018-07-27
- **Final completion:** 2020-07-23
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374488, "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03374488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*